Development of an Opioid Withdrawal Clinical Outcome Assessment
NCT ID: NCT07094672
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
30 participants
OBSERVATIONAL
2026-07-01
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
NCT05027919
Resilience Among Individuals With Opioid Use Disorder
NCT06954402
Evaluation of Clinical Decision Support in Opioid Tapering
NCT06527079
PRoducing Outcome Measures for OTP Quality Improvement
NCT07214389
Harnessing Placebo Effects in Methadone Treatment
NCT02941809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary outcome will be cognitive interviews, which will be conducted within 8 hours of each observation period ending to query all possible symptoms associated with the withdrawal experience.
Participants will be offered referrals to aftercare prior to study discharge and transitions to treatment programs will be facilitated whenever possible.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WIthdrawal assessment_precipitated session
Assessment of withdrawal following elicitation
No interventions assigned to this group
Withdrawal assessment_spontaneous
Assessment of withdrawal during a period of opioid abstinence
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent in English
* Has experience with opioid withdrawal at least once in the past 30 days
Exclusion Criteria
* Being pregnant or breastfeeding
* History of psychosis or mania as determined by the MINI
* Exhibiting suicidal behavior in the past 30 days as determined by the C-SSRS
* Circumstances that could interfere with study participation
* Previously participated in affiliated Focus Group study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kelly Dunn
Director, Kahlert Institute for Addiction Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kahlert Institute for Addiction Medicine
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00114126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.